Viyash Scientific Limited
(Formerly known as Sequent Scientific Limited)
Registered Office:
3rd Floor, Srivalli's Corporate, Plot No.290, Road No.6,
Sy.No.33, 34P to 39, Guttala Begumpet, Jubilee Hills,
Hyderabad, Shaikpet, Telangana, India-500033
T: +91 40 23635000,
E: investorrelations@viyash.com
Website: www.viyash.com
CIN: L99999TS1985PLC196357

November 13, 2026

To,

BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort,
Mumbai - 400 001

National Stock Exchange of India Limited
Exchange Plaza,
Bandra-Kurla Complex,
Bandra (East),
Mumbai - 400 051

Scrip code: 512529

Symbol: VIYASH

Dear Sir/ Madam,

Subject: Investor Presentation for Q2 FY27

Dear Sir/Madam,

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose herewith the Investor Presentation on Q2 FY27 Financial Results.

This is for your information and appropriate dissemination.

Thanking you,

Yours faithfully,
For **Viyash Scientific Limited**
(Formerly known as Sequent Scientific Limited)

YOSHITA SUSMIT VORA

Yoshita Vora
Company Secretary & Compliance Officer

INVESTOR PRESENTATION

Q2 FY27

VIYASH SCIENTIFIC LIMITED

November 13, 2026

Marching ahead as an Integrated platform

"Viyash Scientific has delivered yet another stellar quarter with H1 revenue up 17.8% and H1 profit after tax (PAT) at INR 164 Cr, up ~50% from last year. H1 adjusted PAT with normalized ESOP cost is INR 204 Cr*. The completion of acquisition of BioForLife in Italy strengthens our companion animal platform. We are also investing in new oncology capabilities, in-house companion animal manufacturing facility and expanding our API capacity to meet customer demand.

Our focus remains on disciplined execution, R&D-led growth and sustainable value creation for customers and stakeholders."

Dr Hari Babu Bodepudi
Managing Director and Group CEO

Notes: * Assuming normalized annual ESOP cost at INR 25 Cr

Q2FY27 Financial Snapshot

Viyash Scientific : H1 FY27 Performance Highlights

All values in ₹ Mn

Revenues

₹19,343

Million

+17.8% YoY

EBITDA[1]

₹4,124

Million

+29.9 % YoY

EBITDA Margin

21.3%

200 bps YoY

Net Debt to LTM EBITDA[1]

0.0x

Net Debt- ₹ 261 Mn

0.7x in H1 FY26

Net Debt - ₹ 4,095 Mn

Notes: 1. EBITDA before ESOP cost

Viyash Scientific : Q2 FY27 Performance Highlights

All values in ₹ Mn

Revenues

₹9,879

Million

+16.2% YoY

EBITDA[1]

₹2,077

Million

+10.3 % YoY

EBITDA Margin

21.0%

-110 bps YoY

Net Debt to LTM EBITDA[1]

0.0x

Net Debt- ₹ 261 Mn

0.1x in Q1 FY27


Net Debt - ₹ 861 Mn

Notes: 1. EBITDA before ESOP cost


Sustained Sales Growth with Consistent EBITDA Expansion

All values in ₹ Mn


SALES




GROSS MARGIN



EBITDA[1]



Net Debt to EBITDA[1]



Notes: 1. EBITDA before ESOP cost

Viyash Consolidated Financials

All values in ₹ Mn

Particulars	Q2 FY27	Q2 FY26	Grw YoY %	Q1 FY27	Grw QoQ %	H1 FY27	H1 FY26	Grw YoY %
Revenue from Operations	9,879	8,503	*16.2%*	9,464	*4.4%*	19,343	16,419	*17.8%*
Material Consumption	(4,574)	(3,785)		(4,343)		(8,917)	(7,590)	
Gross Margin	**5,305**	**4,719**	***12.4%***	**5,121**	***3.6%***	**10,426**	**8,830**	***18.1%***
% Gross margin	*53.7%*	*55.5%*		*54.1%*		*53.9%*	*53.8%*	
Employee Benefit Expenses	(1,428)	(1,292)	10.5%	(1,381)	3.4%	(2,808)	(2,550)	10.1%
Operating Expenses	(1,792)	(1,587)	12.9%	(1,696)	5.6%	(3,488)	(3,153)	10.6%
Exchange Gain / (Loss)	(9)	43		3		(6)	49	
EBITDA[1]	**2,077**	**1,883**	***10.3%***	**2,047**	***1.4%***	**4,124**	**3,176**	***29.9%***
% EBITDA	*21.0%*	*22.1%*		*21.6%*		*21.3%*	*19.3%*	
ESOP cost	(421)	(100)		(246)		(667)	(230)	
Exceptional Items	-	(17)		-		-	(30)	
IndAS 29 Adjustment	(16)	(8)		(14)		(30)	30	
Other Income	127	32		80		207	88	
Finance Cost	(137)	(175)		(125)		(262)	(379)	
Depreciation	(453)	(591)		(618)		(1,071)	(1,147)	
Earnings Before Tax	**1,177**	**1,024**	***15.0%***	**1,124**	***4.7%***	**2,301**	**1,507**	***52.7%***
% Earning Before Tax	*11.9%*	*12.0%*		*11.9%*		*11.9%*	*9.2%*	
Taxes	(330)	(295)		(331)		(662)	(410)	
Earnings After Tax	**847**	**729**	***16.1%***	**793**	***6.8%***	**1,639**	**1,098**	***49.4%***

- Step up in Animal health R&D investment to support new products for Companion Animals

- ESOP cost increase on account of incremental ESOP grants pursuant to the scheme of amalgamation

Notes: 1. EBITDA before ESOP cost

Business Updates





Revenue Performance Key highlights

All values in ₹ Mn

Revenue Distribution	Q2			Q1		H1		
	FY27	FY26	YoY %	FY27	QnQ %	FY27	FY26	YoY %
Formulations	**5,587**	**4,687**	***19%***	**5,547**	*1%*	**11,134**	**8,858**	*26%*
Europe	1,864	1,532	*22%*	1,847	*1%*	3,711	3,211	*16%*
Emerging Markets	2,030	1,457	*39%*	2,008	*1%*	4,038	2,898	*39%*
India	504	362	*39%*	430	*17%*	934	625	*49%*
USA	1,189	1,337	*-11%*	1,262	*-6%*	2,451	2,124	*15%*
APIs	**4,154**	**3,721**	***12%***	**3,833**	*8%*	**7,987**	**7,413**	***8%***
Other Sales	118	62		76		193	153	
Global Sales	**9,859**	**8,470**	***16%***	**9,456**	***4%***	**19,314**	**16,424**	***18%***
One Offs #		-		-		-	(56)	
Adjustment - Ind AS 29*	21	33		8		29	51	
Reported Sales	**9,879**	**8,503**	***16%***	**9,464**	***4%***	**19,343**	**16,419**	***18%***

*Adjustment on account of hyperinflation in Turkey as per Ind AS 29

Provision for customer claim on shipments in prior years

BioForLife acquisition in Italy

Acquisition of BioForLife in Italy aligned with our Companion strategy

01 Provides access to a large companion animal market in Italy

02 Companion animal portfolio (85-90 products) that can be extended to other core markets

03 Launch our global pipeline in Italy; salesforce has 85% vet clinic coverage in Italy

04 Strong talent addition in Italy



Execution of SPA: 21st July 2026
Completion of Acquisition: 1st October 2026

New Oncology FDF R&D Center, Jeedimetla, Hyderabad

Viyash

Building an end-to-end oncology platform, from API to finished dosage







OEB 4 & 5

High-potent containment

Isolator-based facility to handle high-potent molecules

Pilot-scale

Batch capability

Finished-dosage R&D centre that can run pilot-scale batches

Oncology value chain


Aiming to be a strong long-term player in Human Formulation

API development	API manufacturing	**Finished product development** New R&D Center	**Finished product manufacturing**

New Dedicated Companion Animal Facility, Ambernath

Day-1 launch readiness: In-house manufacturing for our companion animal pipeline







1

Commencement

Capex initiated for new tablet facility

2

Q1 FY28

Expected commissioning & start of production

New Manufacturing Block at Viyash-IV, Nalgonda

Adding API capacity to meet rising demand and support backward integration







128 KL **Additional capacity**

New block adds capacity to support rising demand for select APIs

Approved

All necessary approvals received for the new block

Awards & Recognition



Best ESG Performance Award

National Awards for Excellence



CSR Excellence in Healthcare & Community Development

National Awards for Excellence

Key Strategic Priorities by Segment

Animal Health Formulations

Grow through companion animals and geographical expansion

- Integrate BioForLife (“BFL”) and cross-sell Alivira & BFL products
- Day 1 launch of companion animal new products
- Enter new markets, Vietnam expansion initiated
- Use acquisitions to fill portfolio gaps and market access

Human Health Formulations

Grow through complex and high-potent products

- Develop complex and high-potent products
- Move high-volume products to India for cost advantage
- Make our own APIs for key formulation products
- Build an end-to-end oncology business

API & CDMO

Strengthen our core business

- Develop complex molecules for Human Health & full portfolio for Animal Health
- Win new customers for key molecules
- Supply APIs for our own formulations
- Pursue new CDMO opportunities with partners

Viyash at a Glance





Who we are?

We are an integrated pharmaceutical platform across animal and human health backed by science and IP

Diversified Product Portfolio

API - 110+

Human Health - 35+

Animal Health- 140+

Global Presence

150+ Countries

250+ global customers

Backward Integration

16 Manufacturing facilities

Backward Integration for key APIs

IP & Technology Driven

335+ Scientists

190+ Patents Filed

1,000+ Registrations

Strong Management Team

Industry leaders with 30+ years experience

Viyash Scientific: Key Milestones

Viyash Life Sciences

Foundation & Early Growth
2019–2020

Founded in February 2019 by Dr Haribabu Bodepudi.

Rapid expansion through acquisitions of Vindhya Pharma and Vandana Life Sciences, and establishment of API R&D infrastructure.


Scale & Expansion
2021

Acquisition of Mylan's API and formulation units in Vizag and Mumbai. Strategic investment by the Carlyle Group.

Acquisition of Symed Labs and Appco Pharma LLC, strengthening global capabilities

Integration & Global Reach
2022–2025

Unified manufacturing operations, expanded R&D to over 200 scientists, filed 175+ patents*, and strengthened global partnerships and regulatory capabilities.



Viyash Scientific Limited

2025 onwards

Merger Integration & Transformation
2026-2027

Acquisition of BioForLife in Italy

SeQuent Scientific

Foundation & Evolution
1985–2013

Originated as Visistha Trades, transitioned into a focused pharmaceutical and animal health company, and rebranded as SeQuent Scientific Limited.


Global Expansion
2014–2019

Established Alivira as a dedicated animal health brand. Expanded operations across Europe, Latin America, and emerging markets with USFDA veterinary API approvals.

Specialization & Growth
2020–2025

Focused on new geographies and specialized animal healthcare segments, building a strong global manufacturing and distribution network.

16 world class manufacturing facilities



Our R&D landscape



R&D centre	Location	Capabilities / dosage forms	Technologies & infrastructure	R&D members
API R&D	India (Hyderabad, Telangana)	• Scalable complex APIs incl. high-potent (OEB 4/5) & cytotoxic; iron-complex, inorganic & complex molecules	• 20+ chemical R&D labs; dedicated process-safety lab; high-end analytical equipment for process dev & validation	225+
Formulation R&D – Human Health (Viyash / Appco)	India	• OSD (Non-Onco) & Onco-Cytotoxic; generics plus complex pharmaceuticals	• Formulation development, analytical method development, tech transfer, QA, regulatory affairs	60+
Formulation R&D – Animal Health (Alivira)	India, Spain, Turkey	• Generic & complex dosage forms — solid, liquid & sterile (oral solutions/suspensions, powders, premixes)	• Formulation development, analytical method development, tech transfer, QA, regulatory filings	55+

Board of Directors



Dr. Kamal Sharma
Chairman and Independent Director



Dr. Haribabu Bodepudi
Managing Director and Group CEO



Mr. Rajaram Narayanan
Executive Director and CEO- Animal Health



Mr. Anuj Poddar
Non-executive Director



Mr. Amit Jain
Non-executive Director



Mr. Abhiroop Jayanthi
Non-executive Director



Mr. Milind Sarwate
Independent Director



Ms. Revati Kasture
Independent Director



Mr. Srinivas Vasireddy
Executive Director

For details, feel free to contact:

Yoshita Vora

Company Secretary

+91 22 4111 4777

investorrelations@viyash.com

Abhishek Singhal

Investor Relations Consultant

abhishek@arunya.co.in

Registered Office: Plot No.290, Srivalli's Corporate, Road No.6, Kakatiya Hills, Madhapur Hyderabad Rangareddy TG 500081, India

Websites: www.viyash.com | CIN: L99999TS1985PLC196357 | BSE Code:512529 | NSE: VIYASH

ISIN: INE807F01027

Certain statements in this document that are not historical facts are forward looking statements. Such forward-looking statements are subject to certain risks and uncertainties like government actions, local, political or economic developments, technological risks, and many other factors that could cause actual results to differ materially from those contemplated by the relevant forward-looking statements. Viyash Scientific Ltd. will not be in any way responsible for any action taken based on such statements and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.



Thank You

Plot No.290, Srivalli's Corporate, Road No.6, Kakatiya Hills, Madhapur Hyderabad Rangareddy TG 500081, India

info@viyash.com | www.viyash.com

Copyright © 2021. Viyash. All Rights Reserved.